Johnson & Johnson (JNJ) Competitors

Eli Lilly and Company (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership, community ranking and profitability.

Which has higher valuation & earnings, LLY or JNJ?

Johnson & Johnson has higher revenue and earnings than Eli Lilly and Company. Johnson & Johnson is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$45.04B	16.92	$10.59B	$11.71	68.63
Johnson & Johnson	$88.82B	4.16	$14.07B	$6.65	23.04

Do analysts rate LLY or JNJ?

Eli Lilly and Company presently has a consensus price target of $1,009.72, suggesting a potential upside of 25.63%. Johnson & Johnson has a consensus price target of $171.33, suggesting a potential upside of 11.80%. Given Eli Lilly and Company's stronger consensus rating and higher probable upside, equities analysts clearly believe Eli Lilly and Company is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	0 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.85
Johnson & Johnson	0 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.56

Is LLY or JNJ more profitable?

Eli Lilly and Company has a net margin of 23.51% compared to Johnson & Johnson's net margin of 18.20%. Eli Lilly and Company's return on equity of 85.24% beat Johnson & Johnson's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	23.51%	85.24%	16.19%
Johnson & Johnson	18.20%	34.24%	13.63%

Do insiders & institutionals hold more shares of LLY or JNJ?

82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has more risk & volatility, LLY or JNJ?

Eli Lilly and Company has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500.

Is LLY or JNJ a better dividend stock?

Eli Lilly and Company pays an annual dividend of $6.00 per share and has a dividend yield of 0.7%. Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.2%. Eli Lilly and Company pays out 51.2% of its earnings in the form of a dividend. Johnson & Johnson pays out 74.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and Company has increased its dividend for 11 consecutive years and Johnson & Johnson has increased its dividend for 63 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Does the media refer more to LLY or JNJ?

In the previous week, Johnson & Johnson had 5 more articles in the media than Eli Lilly and Company. MarketBeat recorded 149 mentions for Johnson & Johnson and 144 mentions for Eli Lilly and Company. Eli Lilly and Company's average media sentiment score of 0.94 beat Johnson & Johnson's score of 0.76 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eli Lilly and Company	93 Very Positive mention(s)	21 Positive mention(s)	14 Neutral mention(s)	13 Negative mention(s)	3 Very Negative mention(s)	Positive
Johnson & Johnson	82 Very Positive mention(s)	12 Positive mention(s)	26 Neutral mention(s)	19 Negative mention(s)	10 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in LLY or JNJ?

Eli Lilly and Company received 96 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 70.57% of users gave Eli Lilly and Company an outperform vote while only 64.93% of users gave Johnson & Johnson an outperform vote.

Company	Underperform	Outperform
Eli Lilly and Company	Outperform Votes 1218 70.57%	Underperform Votes 508 29.43%
Johnson & Johnson	Outperform Votes 1122 64.93%	Underperform Votes 606 35.07%

Summary

Eli Lilly and Company beats Johnson & Johnson on 14 of the 22 factors compared between the two stocks.